Sana Biotechnology (SANA) Financials

$1.87 -0.02 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.04 (+2.41%)

As of 07:56 PM Eastern

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-269	-283	-267
Consolidated Net Income / (Loss)	-269	-283	-267
Net Income / (Loss) Continuing Operations	-269	-283	-267
Total Pre-Tax Income	-269	-283	-267
Total Operating Income	-273	-293	-273
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	273	293	273
Selling, General & Admin Expense	72	73	64
Research & Development Expense	201	220	209
Total Other Income / (Expense), net	3.09	9.89	5.96
Interest & Investment Income	3.76	9.94	10
Other Income / (Expense), net	-0.67	-0.05	-4.51
Basic Earnings per Share	($1.43)	($1.46)	($1.16)
Weighted Average Basic Shares Outstanding	188.34M	194.54M	230.89M
Diluted Earnings per Share	($1.43)	($1.46)	($1.16)
Weighted Average Diluted Shares Outstanding	188.34M	194.54M	230.89M
Weighted Average Basic & Diluted Shares Outstanding	191.36M	220.45M	225.02M

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-85	-80	-82	-114	0.98	-88	-107	-50	-60	-49
Consolidated Net Income / (Loss)	-85	-80	-82	-114	0.98	-88	-107	-50	-60	-49
Net Income / (Loss) Continuing Operations	-85	-80	-82	-114	0.98	-88	-107	-50	-60	-49
Total Pre-Tax Income	-85	-80	-82	-114	0.98	-88	-107	-50	-60	-49
Total Operating Income	-86	-82	-84	-116	-2.18	-91	-111	-49	-62	-51
Total Operating Expenses	86	82	84	116	2.18	91	111	49	62	51
Selling, General & Admin Expense	16	23	17	17	19	21	16	16	14	17
Research & Development Expense	71	58	67	100	-17	70	94	33	48	34
Total Other Income / (Expense), net	1.07	1.35	1.98	2.29	3.17	2.46	3.25	-0.92	1.84	1.80
Interest & Investment Income	1.17	1.61	1.98	2.37	2.86	2.73	3.03	3.20	2.58	1.66
Other Income / (Expense), net	-0.11	-0.27	-	-0.08	0.30	-	0.22	-4.12	-0.74	0.14
Basic Earnings per Share	($0.45)	($0.42)	($0.43)	($0.59)	$0.00	($0.44)	($0.49)	($0.21)	($0.25)	($0.21)
Weighted Average Basic Shares Outstanding	189.30M	188.34M	191.23M	192.54M	196.98M	194.54M	217.29M	234.44M	235.41M	230.89M
Diluted Earnings per Share	($0.45)	($0.42)	($0.43)	($0.59)	$0.00	($0.44)	($0.49)	($0.21)	($0.25)	($0.21)
Weighted Average Diluted Shares Outstanding	189.30M	188.34M	191.23M	192.54M	200.47M	194.54M	217.29M	234.44M	235.41M	230.89M
Weighted Average Basic & Diluted Shares Outstanding	190.73M	191.36M	191.50M	196.94M	197.13M	220.45M	221.50M	222.47M	223.27M	225.02M

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-75	-50	-5.95
Net Cash From Operating Activities	-290	-254	-223
Net Cash From Continuing Operating Activities	-290	-254	-223
Net Income / (Loss) Continuing Operations	-269	-283	-267
Consolidated Net Income / (Loss)	-269	-283	-267
Depreciation Expense	16	25	17
Non-Cash Adjustments To Reconcile Net Income	41	35	36
Changes in Operating Assets and Liabilities, net	-77	-30	-10
Net Cash From Investing Activities	211	172	17
Net Cash From Continuing Investing Activities	211	172	17
Purchase of Property, Plant & Equipment	-21	-20	-33
Purchase of Investments	-79	-158	-226
Sale and/or Maturity of Investments	310	350	277
Other Investing Activities, net	0.00	0.00	0.00
Net Cash From Financing Activities	4.91	32	200
Net Cash From Continuing Financing Activities	4.91	32	200
Issuance of Common Equity	4.91	32	192
Other Financing Activities, net	0.00	0.00	7.74

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-31	13	-16	13	-12	-35	44	-42	-7.96	0.57
Net Cash From Operating Activities	-65	-76	-79	-59	-64	-52	-66	-59	-52	-47
Net Cash From Continuing Operating Activities	-65	-76	-79	-59	-64	-52	-66	-59	-52	-47
Net Income / (Loss) Continuing Operations	-85	-80	-82	-114	0.98	-88	-107	-50	-60	-49
Consolidated Net Income / (Loss)	-85	-80	-82	-114	0.98	-88	-107	-50	-60	-49
Depreciation Expense	4.02	4.20	4.35	4.45	4.50	11	3.75	3.90	4.06	5.69
Non-Cash Adjustments To Reconcile Net Income	10	11	9.19	10	8.41	7.82	7.55	13	9.89	5.39
Changes in Operating Assets and Liabilities, net	6.01	-11	-11	41	-77	17	31	-26	-5.84	-9.18
Net Cash From Investing Activities	32	88	63	43	51	15	-77	5.82	42	47
Net Cash From Continuing Investing Activities	32	88	63	43	51	15	-77	5.82	42	47
Purchase of Property, Plant & Equipment	-4.35	-4.60	-2.18	-1.58	-2.23	-14	-16	-13	-4.09	-0.44
Purchase of Investments	-18	-15	-20	-51	-60	-26	-114	-63	-36	-13
Sale and/or Maturity of Investments	54	108	85	95	114	55	53	81	82	61
Net Cash From Financing Activities	1.62	1.06	0.24	30	0.19	1.72	186	11	2.08	0.64
Net Cash From Continuing Financing Activities	1.62	1.06	0.24	30	0.19	1.72	186	11	2.08	0.64
Issuance of Common Equity	1.62	1.06	0.24	30	0.19	1.72	186	3.00	1.91	0.70
Other Financing Activities, net	-	-	-	-	-	-	-	-	0.17	-0.06

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	823	565	501
Total Current Assets	444	214	161
Cash & Equivalents	177	134	128
Restricted Cash	6.10	3.83	3.83
Short-Term Investments	247	72	25
Prepaid Expenses	14	4.49	4.48
Plant, Property, & Equipment, net	67	71	77
Total Noncurrent Assets	311	281	263
Long-Term Investments	10	0.00	0.00
Goodwill	141	141	141
Intangible Assets	59	59	59
Other Noncurrent Operating Assets	101	81	63
Total Liabilities & Shareholders' Equity	823	565	501
Total Liabilities	323	278	251
Total Current Liabilities	112	64	45
Short-Term Debt	55	0.00	0.00
Accounts Payable	2.86	4.11	5.21
Accrued Expenses	15	23	13
Current Employee Benefit Liabilities	26	24	14
Other Current Liabilities	12	13	13
Total Noncurrent Liabilities	212	213	205
Capital Lease Obligations	96	91	82
Other Noncurrent Operating Liabilities	116	122	123
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	499	288	251
Total Preferred & Common Equity	499	288	251
Preferred Stock	0.00	0.00	0.00
Total Common Equity	499	288	251
Common Stock	1,558	1,626	1,855
Retained Earnings	-1,055	-1,338	-1,605
Accumulated Other Comprehensive Income / (Loss)	-4.33	-0.06	0.01

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	898	747	707	631	681	619	559
Total Current Assets	500	370	339	280	321	263	210
Cash & Equivalents	163	160	174	168	177	135	127
Restricted Cash	6.10	6.10	6.10	3.83	3.83	3.83	3.83
Short-Term Investments	322	189	152	100	134	117	72
Prepaid Expenses	8.40	15	6.61	7.12	6.35	7.98	7.31
Plant, Property, & Equipment, net	67	64	63	68	82	86	83
Total Noncurrent Assets	331	313	306	284	278	269	266
Long-Term Investments	30	10	0.00	0.00	0.00	0.00	0.00
Goodwill	141	141	141	141	141	141	141
Intangible Assets	59	59	59	59	59	59	59
Other Noncurrent Operating Assets	100	103	106	84	79	69	67
Total Liabilities & Shareholders' Equity	898	747	707	631	681	619	559
Total Liabilities	332	319	352	266	306	279	267
Total Current Liabilities	115	103	112	67	53	51	47
Short-Term Debt	59	57	58	0.00	0.00	0.00	0.00
Accounts Payable	3.99	2.33	3.09	9.93	6.10	3.82	2.99
Accrued Expenses	15	13	18	19	20	21	15
Current Employee Benefit Liabilities	25	17	20	24	14	16	18
Other Current Liabilities	12	13	13	13	13	10.00	11
Total Noncurrent Liabilities	217	216	240	199	253	228	220
Capital Lease Obligations	100	102	100	83	93	89	85
Other Noncurrent Operating Liabilities	117	114	140	116	160	140	134
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	566	428	355	366	375	340	292
Total Preferred & Common Equity	566	428	355	366	375	340	292
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	566	428	355	366	375	340	292
Common Stock	1,547	1,567	1,607	1,616	1,821	1,836	1,848
Retained Earnings	-974	-1,137	-1,251	-1,250	-1,446	-1,496	-1,556
Accumulated Other Comprehensive Income / (Loss)	-6.41	-2.14	-0.87	-0.20	-0.02	-0.02	0.05

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	25.45%	-4.28%	3.27%
EBIT Growth	23.38%	-7.30%	5.44%
NOPAT Growth	23.63%	-7.55%	6.97%
Net Income Growth	24.29%	-5.11%	5.82%
EPS Growth	33.18%	-2.10%	20.55%
Operating Cash Flow Growth	-15.53%	12.57%	12.00%
Free Cash Flow Firm Growth	22.71%	40.35%	-20.22%
Invested Capital Growth	67.03%	-19.50%	3.81%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	10.37%	-0.68%	10.25%
EBIT Q/Q Growth	9.58%	-3.12%	11.28%
NOPAT Q/Q Growth	9.76%	-3.11%	12.72%
Net Income Q/Q Growth	10.10%	-2.78%	12.77%
EPS Q/Q Growth	-13.49%	-1.39%	16.55%
Operating Cash Flow Q/Q Growth	10.50%	8.68%	2.10%
Free Cash Flow Firm Q/Q Growth	32.41%	4.89%	9.06%
Invested Capital Q/Q Growth	3.53%	-4.21%	0.41%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	98.62%	96.61%	96.22%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-43.90%	-72.00%	-99.17%
Cash Return on Invested Capital (CROIC)	-163.64%	-86.46%	-114.34%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-43.90%	-72.00%	-99.17%
Return on Equity Simple (ROE_SIMPLE)	-53.97%	-98.52%	-106.49%
Net Operating Profit after Tax (NOPAT)	-191	-205	-191
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-17.65%	-38.35%	-78.69%
Return On Investment Capital (ROIC_SIMPLE)	-29.33%	-54.23%	-57.47%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-273	-293	-277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-258	-269	-260
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.51	2.80	1.45
Price to Tangible Book Value (P/TBV)	2.52	9.17	7.18
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.21	4.05	1.65
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.30	0.32	0.33
Long-Term Debt to Equity	0.19	0.32	0.33
Financial Leverage	-0.73	-0.52	-0.36
Leverage Ratio	1.59	1.76	1.98
Compound Leverage Factor	1.57	1.70	1.91
Debt to Total Capital	23.24%	24.02%	24.58%
Short-Term Debt to Total Capital	8.51%	0.00%	0.00%
Long-Term Debt to Total Capital	14.74%	24.02%	24.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	76.76%	75.98%	75.42%
Debt to EBITDA	-0.59	-0.34	-0.31
Net Debt to EBITDA	1.12	0.44	0.29
Long-Term Debt to EBITDA	-0.37	-0.34	-0.31
Debt to NOPAT	-0.79	-0.44	-0.43
Net Debt to NOPAT	1.51	0.58	0.39
Long-Term Debt to NOPAT	-0.50	-0.44	-0.43
Altman Z-Score	-1.01	-2.97	-5.16
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.99	3.31	3.54
Quick Ratio	3.80	3.18	3.36
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-275	-164	-197
Operating Cash Flow to CapEx	-1,389.39%	-1,265.88%	-667.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	210	169	176
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	84	-41	6.46
Enterprise Value (EV)	464	686	289
Market Capitalization	753	804	364
Book Value per Share	$2.62	$1.46	$1.12
Tangible Book Value per Share	$1.57	$0.44	$0.23
Total Capital	651	378	332
Total Debt	151	91	82
Total Long-Term Debt	96	91	82
Net Debt	-289	-118	-75
Capital Expenditures (CapEx)	21	20	33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-42	-60	-41
Debt-free Net Working Capital (DFNWC)	388	149	115
Net Working Capital (NWC)	333	149	115
Net Nonoperating Expense (NNE)	79	78	76
Net Nonoperating Obligations (NNO)	-289	-118	-75
Total Depreciation and Amortization (D&A)	16	25	17
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.43)	($1.46)	($1.16)
Adjusted Weighted Average Basic Shares Outstanding	188.34M	194.54M	230.89M
Adjusted Diluted Earnings per Share	($1.43)	($1.46)	($1.16)
Adjusted Weighted Average Diluted Shares Outstanding	188.34M	194.54M	230.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	191.36M	220.45M	225.02M
Normalized Net Operating Profit after Tax (NOPAT)	-191	-205	-191
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-2.16%	27.68%	-182.92%	-61.50%	103.19%	-1.92%	-33.95%	55.69%	-2,329.91%	43.25%
EBIT Growth	-3.44%	26.07%	-164.42%	-59.19%	97.82%	-10.44%	-31.48%	54.03%	-3,228.17%	44.02%
NOPAT Growth	-3.30%	26.50%	-165.27%	-59.51%	96.38%	-10.80%	-31.73%	57.54%	-1,882.24%	43.87%
Net Income Growth	-2.23%	27.35%	-161.14%	-57.32%	101.16%	-9.54%	-30.87%	55.88%	-6,189.84%	44.31%
EPS Growth	2.17%	-68.00%	-152.94%	-51.28%	100.00%	-4.76%	-13.95%	64.41%	0.00%	52.27%
Operating Cash Flow Growth	-28.34%	30.91%	-2.01%	17.74%	1.92%	31.69%	17.21%	0.44%	18.46%	9.23%
Free Cash Flow Firm Growth	-289.05%	23.06%	14.78%	83.19%	109.46%	84.19%	95.03%	47.50%	-271.47%	-87.73%
Invested Capital Growth	2,634.47%	67.03%	132.71%	-15.22%	-12.99%	-19.50%	-30.84%	-4.92%	-0.96%	3.81%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-18.72%	5.37%	-2.37%	-40.42%	102.34%	-3,127.66%	-34.54%	53.54%	-17.84%	22.95%
EBIT Q/Q Growth	-18.04%	4.91%	-2.43%	-38.45%	98.39%	-4,725.29%	-21.95%	51.59%	-16.84%	18.84%
NOPAT Q/Q Growth	-18.22%	5.10%	-2.77%	-38.35%	97.32%	-2,808.45%	-22.19%	55.41%	-25.09%	17.64%
Net Income Q/Q Growth	-17.46%	5.49%	-2.09%	-38.81%	100.86%	-9,054.98%	-21.97%	53.21%	-19.15%	18.11%
EPS Q/Q Growth	-15.38%	6.67%	-2.38%	-37.21%	100.00%	0.00%	-11.36%	57.14%	-19.05%	16.00%
Operating Cash Flow Q/Q Growth	9.35%	-17.39%	-4.21%	25.82%	-8.08%	18.24%	-26.32%	10.80%	11.48%	8.99%
Free Cash Flow Firm Q/Q Growth	11.74%	44.68%	-30.66%	73.64%	149.64%	-192.51%	58.93%	-178.37%	-62.12%	-1.28%
Invested Capital Q/Q Growth	-5.16%	3.53%	5.25%	-17.96%	-2.67%	-4.21%	-9.58%	12.79%	1.38%	0.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.06%	100.00%	100.00%	99.95%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.64%	98.03%	97.65%	97.96%	-52.40%	97.29%	97.25%	94.01%	95.87%	96.74%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-42.94%	-43.90%	-56.67%	-72.73%	-59.15%	-72.00%	-76.82%	-70.51%	-92.90%	-99.17%
Cash Return on Invested Capital (CROIC)	-386.63%	-163.64%	-223.45%	-113.75%	-90.84%	-86.46%	-83.06%	-94.85%	-123.33%	-114.34%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-42.94%	-43.90%	-56.67%	-72.73%	-59.15%	-72.00%	-76.82%	-70.51%	-92.90%	-99.17%
Return on Equity Simple (ROE_SIMPLE)	-52.96%	0.00%	-74.76%	-101.87%	-75.33%	0.00%	-82.26%	-72.10%	-104.56%	0.00%
Net Operating Profit after Tax (NOPAT)	-60	-57	-59	-81	-2.18	-63	-78	-35	-43	-36
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.18%	-5.20%	-5.73%	-10.89%	1.15%	-12.13%	-13.98%	-9.25%	-10.90%	-13.97%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.80%	-	-	-	-16.76%	-	-	-	-10.72%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-86	-82	-84	-116	-1.88	-91	-111	-53	-63	-51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-82	-78	-80	-112	2.62	-79	-107	-50	-58	-45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.02	1.51	1.46	3.21	2.08	2.80	5.88	3.56	3.16	1.45
Price to Tangible Book Value (P/TBV)	3.12	2.52	2.74	7.35	4.59	9.17	12.57	8.65	9.99	7.18
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.83	2.21	1.89	5.33	3.24	4.05	12.94	6.04	4.61	1.65
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.28	0.30	0.37	0.45	0.23	0.32	0.25	0.26	0.29	0.33
Long-Term Debt to Equity	0.18	0.19	0.24	0.28	0.23	0.32	0.25	0.26	0.29	0.33
Financial Leverage	-0.85	-0.73	-0.72	-0.60	-0.59	-0.52	-0.53	-0.49	-0.47	-0.36
Leverage Ratio	1.53	1.59	1.59	1.69	1.64	1.76	1.78	1.91	1.81	1.98
Compound Leverage Factor	1.51	1.56	1.55	1.65	-0.86	1.72	1.73	1.79	1.73	1.92
Debt to Total Capital	21.96%	23.24%	27.05%	30.89%	18.56%	24.02%	19.85%	20.68%	22.62%	24.58%
Short-Term Debt to Total Capital	8.19%	8.51%	9.75%	11.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	13.77%	14.74%	17.31%	19.51%	18.56%	24.02%	19.85%	20.68%	22.62%	24.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	78.04%	76.76%	72.95%	69.11%	81.44%	75.98%	80.15%	79.32%	77.38%	75.42%
Debt to EBITDA	-0.55	-0.59	-0.51	-0.45	-0.31	-0.34	-0.31	-0.39	-0.30	-0.31
Net Debt to EBITDA	1.26	1.12	0.67	0.49	0.71	0.44	0.75	0.73	0.41	0.29
Long-Term Debt to EBITDA	-0.35	-0.37	-0.33	-0.29	-0.31	-0.34	-0.31	-0.39	-0.30	-0.31
Debt to NOPAT	-0.75	-0.79	-0.70	-0.62	-0.42	-0.44	-0.42	-0.50	-0.39	-0.43
Net Debt to NOPAT	1.72	1.51	0.91	0.67	0.95	0.58	0.99	0.94	0.54	0.39
Long-Term Debt to NOPAT	-0.47	-0.50	-0.45	-0.39	-0.42	-0.44	-0.42	-0.50	-0.39	-0.43
Altman Z-Score	0.74	-0.24	-0.90	-0.69	-0.65	-1.79	1.29	-0.66	-1.83	-3.67
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.36	3.99	3.60	3.02	4.19	3.31	6.07	5.20	4.47	3.54
Quick Ratio	4.23	3.80	3.40	2.91	4.03	3.18	5.88	4.96	4.23	3.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-256	-142	-185	-49	24	-22	-9.20	-26	-42	-42
Operating Cash Flow to CapEx	-1,489.56%	-1,652.91%	-3,643.01%	-3,728.66%	-2,845.95%	-369.92%	-414.21%	-448.38%	-1,266.04%	-10,816.74%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	203	210	221	182	177	169	153	173	175	176
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	196	84	126	-33	-26	-41	-68	-8.94	-1.70	6.46
Enterprise Value (EV)	779	464	419	968	573	686	1,982	1,042	808	289
Market Capitalization	1,141	753	626	1,141	762	804	2,204	1,209	925	364
Book Value per Share	$2.98	$2.62	$2.24	$1.85	$1.86	$1.46	$1.70	$1.53	$1.31	$1.12
Tangible Book Value per Share	$1.93	$1.57	$1.19	$0.81	$0.84	$0.44	$0.80	$0.63	$0.42	$0.23
Total Capital	725	651	587	514	449	378	468	428	378	332
Total Debt	159	151	159	159	83	91	93	89	85	82
Total Long-Term Debt	100	96	102	100	83	91	93	89	85	82
Net Debt	-363	-289	-207	-173	-189	-118	-222	-167	-117	-75
Capital Expenditures (CapEx)	4.35	4.60	2.18	1.58	2.23	14	16	13	4.09	0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-47	-42	-31	-47	-60	-60	-47	-43	-40	-41
Debt-free Net Working Capital (DFNWC)	445	388	324	285	213	149	268	213	163	115
Net Working Capital (NWC)	385	333	267	227	213	149	268	213	163	115
Net Nonoperating Expense (NNE)	25	23	23	33	-3.17	25	30	16	17	13
Net Nonoperating Obligations (NNO)	-363	-289	-207	-173	-189	-118	-222	-167	-117	-75
Total Depreciation and Amortization (D&A)	4.02	4.20	4.35	4.45	4.50	11	3.75	3.90	4.06	5.69
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.45)	($0.42)	($0.43)	($0.59)	$0.00	($0.44)	($0.49)	($0.21)	($0.25)	($0.21)
Adjusted Weighted Average Basic Shares Outstanding	189.30M	188.34M	191.23M	192.54M	196.98M	194.54M	217.29M	234.44M	235.41M	230.89M
Adjusted Diluted Earnings per Share	($0.45)	($0.42)	($0.43)	($0.59)	$0.00	($0.44)	($0.49)	($0.21)	($0.25)	($0.21)
Adjusted Weighted Average Diluted Shares Outstanding	189.30M	188.34M	191.23M	192.54M	200.47M	194.54M	217.29M	234.44M	235.41M	230.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	190.73M	191.36M	191.50M	196.94M	197.13M	220.45M	221.50M	222.47M	223.27M	225.02M
Normalized Net Operating Profit after Tax (NOPAT)	-60	-57	-59	-81	-1.53	-63	-78	-35	-43	-36
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Sana Biotechnology's Financials

When does Sana Biotechnology's financial year end?

According to the most recent income statement we have on file, Sana Biotechnology's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Sana Biotechnology's net income changed over the last 2 years?

In the past 2 years, Sana Biotechnology's net income has ranged from -$283.26 million in 2023 to -$266.76 million in 2024, and is currently -$266.76 million as of their latest financial filing in 2024. See where experts think Sana Biotechnology is headed by visiting Sana Biotechnology's forecast page.

What is Sana Biotechnology's operating income?

Sana Biotechnology's total operating income in 2024 was -$272.72 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $272.72 million

How has Sana Biotechnology revenue changed over the last 2 years?

Over the last 2 years, Sana Biotechnology's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Sana Biotechnology have?

Sana Biotechnology's total liabilities were at $250.52 million at the end of 2024, a 9.8% decrease from 2023, and a 22.5% decrease since 2022.

How much cash does Sana Biotechnology have?

In the past 2 years, Sana Biotechnology's cash and equivalents has ranged from $127.57 million in 2024 to $176.77 million in 2022, and is currently $127.57 million as of their latest financial filing in 2024.

How has Sana Biotechnology's book value per share changed over the last 2 years?

Over the last 2 years, Sana Biotechnology's book value per share changed from 2.62 in 2022 to 1.12 in 2024, a change of -57.1%.

Related Companies

This page (NASDAQ:SANA) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Financials

Frequently Asked Questions About Sana Biotechnology's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Financials

Annual Income Statements for Sana Biotechnology

Quarterly Income Statements for Sana Biotechnology

Annual Cash Flow Statements for Sana Biotechnology

Quarterly Cash Flow Statements for Sana Biotechnology

Annual Balance Sheets for Sana Biotechnology

Quarterly Balance Sheets for Sana Biotechnology

Annual Metrics and Ratios for Sana Biotechnology

Quarterly Metrics and Ratios for Sana Biotechnology

Frequently Asked Questions About Sana Biotechnology's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools